Within the Cyber Knife market, application‑based segmentation accounts for the largest share of revenue, reflecting clinical adoption patterns across anatomical sites. Brain tumor treatments represent the dominant segment, estimated at roughly 30 % of total sales, driven by the technology’s precision in stereotactic radiosurgery for gliomas and metastases. Spinal lesions follow with an estimated 25 % share, where dose conformity reduces risk to the spinal cord. Lung cancer applications contribute about 20 %, leveraging the system’s ability to track respiratory motion in real time. Prostate cancer occupies roughly 15 % of the market, supported by emerging hypofractionated protocols. The remaining 10 % comprises other indications such as pancreatic, liver, and head‑and‑neck tumors, where case volumes are lower but growth rates remain positive. This Cyber Knife segmentation by application directly shapes R&D investment, pricing strategy, and geographic rollout, as each sub‑segment adds distinct incremental value to the overall market size.